Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер unknown, С. 106417 - 106417
Опубликована: Ноя. 1, 2024
Язык: Английский
Pharmaceutics, Год журнала: 2024, Номер 16(2), С. 223 - 223
Опубликована: Фев. 4, 2024
Niosomes are vesicular nanocarriers, biodegradable, relatively non-toxic, stable, and inexpensive, that provide an alternative for lipid-solid carriers (e.g., liposomes). may resolve issues related to the instability, fast degradation, bioavailability, insolubility of different drugs or natural compounds. can be very efficient potential systems specific delivery anticancer, antioxidant, anti-inflammatory, antimicrobial, antibacterial molecules. This review aims present overview their composition, most common formulation techniques, as well recent utilizations in cancer therapy.
Язык: Английский
Процитировано
32
Gels, Год журнала: 2024, Номер 10(1), С. 45 - 45
Опубликована: Янв. 6, 2024
Topical and transdermal drug delivery are advantageous administration routes, especially when treating diseases conditions with a skin etiology. Nevertheless, conventional dosage forms often lead to low therapeutic efficacy, safety issues, patient noncompliance. To tackle these novel topical platforms involving nanotechnology have been developed. This review focuses on the latest advances regarding development of nanoemulgels for application, encapsulating wide variety molecules, including already marketed drugs (miconazole, ketoconazole, fusidic acid, imiquimod, meloxicam), repurposed (atorvastatin, omeprazole, leflunomide), natural-derived compounds (eucalyptol, naringenin, thymoquinone, curcumin, chrysin, brucine, capsaicin), other synthetic molecules (ebselen, tocotrienols, retinyl palmitate), wound healing, appendage infections, inflammatory diseases, cancer, neuropathy, or anti-aging purposes. Developed formulations revealed adequate droplet size, PDI, viscosity, spreadability, pH, stability, release, permeation and/or retention capacity, having more characteristics than current formulations. In vitro in vivo studies established efficacy developed formulations, confirming their potential, making them promising replacement therapies, as possible adjuvant treatments, which might someday effectively reach market help fight highly incident systemic conditions.
Язык: Английский
Процитировано
15
Polymers for Advanced Technologies, Год журнала: 2024, Номер 35(4)
Опубликована: Апрель 1, 2024
Abstract Recent research in drug delivery has significantly advanced our knowledge of liposome and niosome‐based gels, contributing to the dynamic landscape pharmaceutical advancements. The incorporation these vesicular carriers into gel formulations enhanced stability, while prolonging shelf‐life improving bioavailability encapsulated molecules. synergy between liposomes/niosomes matrices, facilitated by a robust structure, provided protective environment, ensuring sustained release prolonged stability. Liposome‐based gels proved be versatile for various therapeutic applications, demonstrating efficiency solubilizing poorly soluble drugs acting as potent penetration enhancers optimal skin delivery. Today, liposomes serves local depots, thus being fundamental condition controlled optimize patient's outcomes. Insights reveal their potential overcoming conventional challenges, positioning them promising platforms targeted due investigations highlight adaptability niosomal encapsulating both hydrophobic hydrophilic drugs, superior stability release. tunable properties also contributed bioadhesion permeation across biological membranes. primary objective this work is present cutting‐edge findings research, highlighting path modern These innovative solutions offer more efficient interventions, addressing ever‐evolving medicine.
Язык: Английский
Процитировано
8
Biomacromolecules, Год журнала: 2024, Номер 25(9), С. 5650 - 5669
Опубликована: Авг. 20, 2024
Liposomes, made up of phospholipid bilayers, are efficient nanocarriers for drug delivery because they can encapsulate both hydrophilic and lipophilic drugs. Conventional cancer treatments sometimes involve considerable toxicities adverse reactions (ADRs), which limits their clinical value. Despite liposomes' promise in addressing these concerns, trials have revealed significant limitations, including stability, targeted distribution, scaling challenges. Recent focused on enhancing liposome formulations to increase therapeutic efficacy while minimizing negative effects. Notably, the approval liposomal medications like Doxil demonstrates potential treatment. However, intricacy preparation requirement comprehensive regulatory remain substantial impediments. Current trial updates show continued efforts improve targeting mechanisms, payload capacity order address issues. The future therapy depends challenges provide patients with more effective safer treatment alternatives.
Язык: Английский
Процитировано
7
Antioxidants, Год журнала: 2024, Номер 13(7), С. 862 - 862
Опубликована: Июль 18, 2024
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that comprises amyloid-beta protein (Aβ) as main component of neuritic plaques. Its deposition considered trigger for AD pathogenesis, progression, and the clinical symptoms cognitive impairment. Some distinct pathological features include phosphorylation tau protein, oxidative stress, mitochondrial dysfunction. These consequences tend to produce reactive oxygen species (ROS), resulting in dysregulation various signaling pathways neuroinflammation neurodegeneration. The relationship between Aβ cascade stress pathogenesis like “chicken egg” story, with etiology regarding these two factors remaining question “which comes first.” However, this review, we have tried our best clarify interconnection mechanisms show precise cause-and-effect relationship. Based on above hallmarks AD, several therapeutic strategies using natural antioxidants, monoclonal antibodies, vaccines are employed anti-Aβ therapy decrease ROS, burden, chronic neuroinflammation, synaptic failure. antioxidants immunotherapeutics demonstrated significant neuroprotective effects symptomatic relief vitro vivo models, well trials AD. none them received final approval enter drug market mitigating In extensively elaborate pitfalls, assurances, important crosstalk concerning current therapy. Additionally, discuss future development more Aβ-targeted approaches optimization treatment mitigation.
Язык: Английский
Процитировано
6
Applied Materials Today, Год журнала: 2023, Номер 35, С. 102001 - 102001
Опубликована: Ноя. 23, 2023
Skin cancer chemotherapeutics often lead to the development of severe cytotoxicity, compelling novel delivery systems not only enhance therapeutic efficacy but also minimize side effects and improve patient compliance. In recent years, topical nanoemulsions have emerged as powerful tools in field skin management. This review delves into potential these innovative formulations revolutionize treatment malignancies, due their unique properties, having relevant advantages, such allowing high drug strength, permeation retention enhancement, biocompatibility, controlled release capacity. Despite skin's formidable permeability challenges, it remains an accessible interface for carriers both locally (topical dermal) systemically (transdermal). Nanoemulsions, once associated primarily with cosmetic applications, are now gaining prominence essential components strategies. explores nanoemulsions, shedding light on ability efficiently deliver a wide range molecules, overcoming lipophilic barriers inherent skin. this comprehensive analysis several distinct studies investigating NEs treatment, diverse array were explored, revealing spectrum characteristics. The PDI spans from minimum 0.105 nm maximum 0.421 nm, reflecting variations droplet size distribution. Droplet sizes exhibit considerable diversity, ranging small 16 larger 200 signifying varied penetration. ZP values further contribute highly favorable (-66.6 mV) less advantageous or near zero values, indicative surface charge As healthcare costs continue escalate, nuanced overview nanoemulsion characteristics provides valuable insights applications targeted melanoma and, lesser extent, non-melanoma cancers. value safer becomes increasingly evident. Here, we focus exclusively role advancing therapy.
Язык: Английский
Процитировано
12
Nano Trends, Год журнала: 2025, Номер 9, С. 100085 - 100085
Опубликована: Янв. 31, 2025
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 243 - 243
Опубликована: Фев. 12, 2025
Background/Objectives: Parkinson's disease (PD) is a progressive neuro-degenerative disorder characterized by α-synuclein aggregation, which promotes neuronal death and accelerates neurodegeneration. Small interfering RNA (siRNA) can reduce levels, but its therapeutic potential limited poor stability delivery challenges. Similarly, Selegiline (Sel), monoamine oxidase-B (MAO-B) inhibitor, has low bioavailability, restricting effectiveness. This study aims to develop an intranasal (IN) albumin-coated liposomal system (C-LipSel-siSNCA2) for the co-delivery of Sel α-synuclein-targeting siRNA (siSNCA2) enhance brain targeting efficacy. Methods: Liposomes were prepared using ethanol injection method optimized via D-optimal design size, charge, encapsulation efficiency (EE%). The formulation was coated with human serum albumin (HSA) stability, cellular uptake, gene silencing. In vivo pharmacokinetics pharmacodynamics assessed in rotenone-induced PD rat model evaluate motor function, biochemical markers, brain-targeting efficiency. Results: Optimized liposomes had particle size 113.5 ± 6.8 nm, zeta 6.2 0.8 mV, high EE% (Sel: 92.35%; siRNA: 78.66%). Albumin coating increased 136.5 10.3 nm shifted -13.5 1.4 enhancing targeting. IN administration achieved 3-fold increase area under concentration-time curve (AUC) versus intravenous delivery. rats, C-LipSel-siSNCA2 improved non-motor functions, restored dopamine enhanced catalase activity, reduced MAO-B mitigating degradation aggregation. Conclusions: non-invasive, dual-action nanoplatform offers targeted therapy PD, combining silencing inhibition, clinical translation neurodegenerative diseases.
Язык: Английский
Процитировано
0
Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 381 - 381
Опубликована: Март 7, 2025
Background/Objectives: Hesperidin (HSP) is a potent phytochemical antioxidant and anti-inflammatory agent that protects against otitis media. However, due to its low solubility bioavailability, suitable delivery method needed overcome these problems. A hydrogel promising nanocarrier for controlled drug in response external stimuli, such as pH variations. Methods: Graphene oxide (GO)-based nanocarriers encapsulate hesperidin were further coated with polylactic-co-glycolic acid/alginate (PLGA-Alg) before being integrated into green neem oil (N.O.) double emulsion produce synergistic effect then characterized by different assays. Results: The exhibited substantial particle size (168 ± 0.32 nm), high encapsulation (89.86 0.23%) zeta potential of 37 0.43 mV. In vitro release studies conducted over 96 h indicated sustained HSP 82% at 5.4 65% 7.4. GO-HSP-loaded formulation exhibits antibacterial activity, evidenced inhibition zones 39 0.02 mm Staphylococcus epidermidis, considerable antifungal activity Candida albicans, an zone 43 0.13 mm, along biofilm activity. demonstrated (5.21 µg/mL) increased cell viability (90–95%) while maintaining cytotoxicity HSE-2 cells. histopathological analysis confirmed treatment the reduced levels pro-inflammatory cytokines (IL-1β, TNF-α, TLR4, IL-6) raised markers (Nrf-2, SOD) vivo rat model Conclusions: GO-based PLGA-Alg deliver enhanced antibacterial, antifungal, properties. This may be used treat media other oxidative stress diseases.
Язык: Английский
Процитировано
0
BioNanoScience, Год журнала: 2025, Номер 15(2)
Опубликована: Март 17, 2025
Язык: Английский
Процитировано
0